Dublin, March 18, 2025 (GLOBE NEWSWIRE) — The “Lymphoma Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Lymphoma Therapeutics was valued at US$17.2 Billion in 2024 and is projected to reach US$25.2 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the lymphoma therapeutics market is driven by several factors. Firstly, the increasing incidence of lymphoma, particularly in aging populations, has heightened the demand for effective treatment options. Secondly, technological advancements in biotechnology and pharmaceuticals have accelerated the development of novel therapies, expanding the arsenal of available treatments. Thirdly, the success of targeted therapies and immunotherapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Moreover, regulatory approvals of breakthrough therapies have streamlined the availability of advanced treatments to patients.
Additionally, there is a growing awareness among patients and healthcare providers about the benefits of early diagnosis and personalized treatment approaches, which further drives market demand. Lastly, the expansion of healthcare infrastructure in emerging economies and the increasing adoption of advanced diagnostic and therapeutic technologies globally ensure sustained market growth. These factors collectively contribute to the dynamic and rapidly evolving landscape of lymphoma therapeutics, promising continued advancements and improved outcomes for patients.
Another significant advancement in lymphoma therapeutics is the development of targeted therapies, which focus on specific genetic mutations and cellular pathways involved in cancer progression. Drugs like brentuximab vedotin and ibrutinib have shown efficacy in treating various forms of lymphoma by interfering with cancer cell growth and survival mechanisms.
These therapies are often used in combination with traditional treatments to enhance their effectiveness and reduce the likelihood of resistance. Additionally, advancements in diagnostic technologies, such as next-generation sequencing, have improved the ability to identify specific genetic alterations in lymphoma, enabling more personalized and precise treatment plans. This precision medicine approach not only improves outcomes but also minimizes side effects, as treatments can be tailored to the individual characteristics of each patient’s cancer.
Lymphoma therapeutics encompass a range of treatment options for lymphoma, a type of cancer that originates in the lymphatic system. There are two primary types of lymphoma: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with the latter being more common. Treatment approaches for lymphoma have evolved significantly over the years, moving from traditional chemotherapy and radiation therapy to more targeted and effective options.
Monoclonal antibodies, such as rituximab, have been game-changers, particularly for NHL, by targeting specific proteins on the surface of cancer cells. In addition, advancements in immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, have opened new avenues for treatment, offering hope for patients who do not respond to conventional therapies. These therapies harness the body’s immune system to fight cancer more effectively and have shown promising results in clinical trials, leading to increased survival rates and improved quality of life for patients.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Non-Hodgkin Lymphoma (NHL) Therapeutics segment, which is expected to reach US$20.5 Billion by 2030 with a CAGR of a 6.3%. The Hodgkin Lymphoma (HL) Therapeutics segment is also set to grow at 7.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $4.6 Billion in 2024, and China, forecasted to grow at an impressive 10.5% CAGR to reach $5.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 406 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $17.2 Billion |
| Forecasted Market Value (USD) by 2030 | $25.2 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Lymphoma Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
MARKET TRENDS & DRIVERS
- Increasing Incidence of Lymphoma Propels Demand for Therapeutics
- Advancements in Immunotherapy Spurs Growth in Lymphoma Treatment Options
- Technological Innovations in Diagnostic Tools Expand Addressable Market Opportunity
- Success of Targeted Therapies Strengthens Business Case for Precision Medicine
- Growing Awareness of Early Diagnosis and Personalized Treatment Drives Adoption
- Expansion of Healthcare Infrastructure in Emerging Economies Generates New Opportunities
- Rising Aging Population Increases Demand for Lymphoma Treatments
- Integration of Next-Generation Sequencing Throws the Spotlight on Precision Oncology
- Combination Therapies Enhance Efficacy and Reduce Resistance in Lymphoma Treatment
- Expansion of Clinical Trials Generates Insights and Accelerates Product Development
- Enhanced Patient Awareness and Advocacy for New Treatments Generates Demand
- Evolution of Treatment Guidelines Impact Market Trends
- Advances in CAR-T Cell Therapy Expand Treatment Options for Refractory Cases
FOCUS ON SELECT PLAYERS:Some of the 93 companies featured in this Lymphoma Therapeutics market report include:
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celgene Corporation
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Forma Therapeutics, Inc.
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals
- Transgene SA
For more information about this report visit https://www.researchandmarkets.com/r/yid2qa
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Lymphoma Therapeutics Market
